Literature DB >> 16870088

Severe tophaceous gout. Characterization of low socioeconomic level patients from México.

J Vázquez-Mellado1, J Cruz, S Guzmán, J Casasola-Vargas, L Lino, R Burgos-Vargas.   

Abstract

OBJECTIVE: To describe a group of patients with frequent tophaceous gout, the variables associated with severe tophaceous gout and to compare them with other patients with gout described elsewhere.
METHODS: We looked for 65 demographic clinical and paraclinical variables from patients with gout who attended our gout clinic from 1995-2000 and were evaluated by the same group of physicians.
RESULTS: Three hundred and sixteen patients were included, 98% males, 82% live in México city, the mean age at onset, educational level and disease duration were 37.5 +/- 12.4, 6.3 +/- 3.9 and 12.6 +/- 10.3 years respectively. Tophaceous gout was present in 62% of the patients with a mean tophi number of 4.7 +/- 6.3 and mean HAQ score 0.13 +/- 0.37. Severe tophaceous gout (>or= 5 tophi) was found in 34% and these patients had significantly: earlier age at onset, longer duration of the disease, lesser frequency of obesity and higher frequency of: intradermal tophi, HAQ > 0.5, hospitalizations, radiographic score III/IV, uric acid under-excretion, renal function impairment and previous (oral and parenteral) auto-prescribed chronic glucocorticoid treatment compared with patients with non-severe tophaceous gout. In the multiple logistic regression the significant variables were renal function impairment (p = 0.000) and previous chronic parenteral glucocorticoid treatment (p = 0.011) .
CONCLUSION: Our patients compared with those from other countries who have earlier age at onset, very low frequency of gout among females, frequent tophaceous gout and severe tophaceous gout. Severe tophaceous gout in this group is associated with renal function impairment and previous chronic parenteral glucocorticoid treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870088

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Severe tophaceous gout and disability: changes in the past 15 years.

Authors:  Carlos Omar López López; Everardo Fuentes Lugo; Everardo Alvarez-Hernández; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Janitzia Vázquez-Mellado
Journal:  Clin Rheumatol       Date:  2016-09-08       Impact factor: 2.980

2.  Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism.

Authors:  Eder Orlando Méndez-Salazar; Gabriela Angélica Martínez-Nava; Janitzia Vázquez-Mellado; Carlos S Casimiro-Soriguer; Joaquin Dopazo; Cankut Çubuk; Yessica Zamudio-Cuevas; Adriana Francisco-Balderas; Karina Martínez-Flores; Javier Fernández-Torres; Carlos Lozada-Pérez; Carlos Pineda; Austreberto Sánchez-González; Luis H Silveira; Ana I Burguete-García; Citlalli Orbe-Orihuela; Alfredo Lagunas-Martínez; Alonso Vazquez-Gomez; Alberto López-Reyes; Berenice Palacios-González
Journal:  Mol Med       Date:  2021-05-24       Impact factor: 6.354

Review 3.  Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.

Authors:  Eder Orlando Méndez-Salazar; Gabriela Angélica Martínez-Nava
Journal:  Rheumatol Int       Date:  2021-09-29       Impact factor: 2.631

4.  Gout disease-specific quality of life and the association with gout characteristics.

Authors:  Jan D Hirsch; Robert Terkeltaub; Dinesh Khanna; Jasvinder Singh; Andrew Sarkin; Micki Shieh; Arthur Kavanaugh; Susan J Lee
Journal:  Patient Relat Outcome Meas       Date:  2010-03-01

5.  Occupational exposure to inorganic dust and risk of gout: a population-based study.

Authors:  Valgerdur Sigurdardottir; Lennart Jacobsson; Linus Schiöler; Anna Svärd; Mats Dehlin; Kjell Toren
Journal:  RMD Open       Date:  2020-07

6.  Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective.

Authors:  Meliha C Kapetanovic; Mohaned Hameed; Aleksandra Turkiewicz; Tuhina Neogi; Tore Saxne; Lennart Jacobsson; Martin Englund
Journal:  RMD Open       Date:  2016-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.